Immune Sensing and Potential Immunotherapeutic Approaches to Control Chromoblastomycosis

• Published in: Journal of fungi (Basel) 2020-12, Vol.7 (1), p.3
• Main Authors: Breda, Leandro C D, Menezes, Isabela G, Paulo, Larissa N M, de Almeida, Sandro Rogério
• Format: Article
• Language: English
• Subjects: chromoblastomycosis; Fonsecaea pedrosoi; immune response; immunotherapy; Review; treatment
• ISSN: 2309-608X; 2309-608X
• DOI: 10.3390/jof7010003

Chromoblastomycosis (CBM) is a neglected, chronic, and progressive subcutaneous mycosis caused by different species of fungi from the Herpotrichiellaceae family. CBM disease is usually associated with agricultural activities, and its infection is characterized by verrucous, erythematous papules, and atrophic lesions on the upper and lower limbs, leading to social stigma and impacts on patients' welfare. The economic aspect of disease treatment is another relevant issue. There is no specific treatment for CBM, and different anti-fungal drug associations are used to treat the patients. However, the long period of the disease and the high cost of the treatment lead to treatment interruption and, consequently, relapse of the disease. In previous years, great progress had been made in the comprehension of the CBM pathophysiology. In this review, we discuss the differences in the cell wall composition of conidia, hyphae, and muriform cells, with a particular focus on the activation of the host immune response. We also highlight the importance of studies about the host skin immunology in CBM. Finally, we explore different immunotherapeutic studies, highlighting the importance of these approaches for future treatment strategies for CBM.